ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mosapride

Also written as “Mosapride Citrate Injection(high)”, “Mosapride Citrate Injection(low)” and “Reference mosapride citrate (GASMOTIN)”.

Its studies are mostly in Gastritis, led by 3 companies.

Drug pageMosapride: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Dec 19, 20133 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only10 open or runningphase 1since Dec 19, 2013Dec 19, 2013none ahead
IlDong Pharmaceuticalits history only10 open or runningphase 1since Mar 12, 2014Mar 12, 2014none ahead
Lunan Pharmaceutical Group11 open or runningphase 2since Jan 8, 2025Jan 8, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lunan Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2025First study: phase 2 study in Postoperative Gastrointestinal DysfunctionFirst studyNCT06782594 · 150 planned · China

TargetBeta

“Serotonin 3 (5-HT3) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist”ChEMBL 37, by rule

Studies

The one study Lunan Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06782594Postoperative Gastrointestinal Dysfunction · China2RecruitingJun 2025150

How it is read

Names in the registry

  • “Mosapride Citrate Injection(high)”, 1 entry
  • “Mosapride Citrate Injection(low)”, 1 entry
  • “Reference mosapride citrate (GASMOTIN)”, 1 entry
  • “Mosapride citrate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.